Affiliation: | 1. Clinical Research Unit, Centre of Internal Medicine, Justus Liebig University, Giessen, Germany Paul Langerhans Institute Dresden (PLID) of the Helmholtz Zentrum München at the University Clinic Carl Gustav Carus of Technische Universität Dresden, Helmholtz Zentrum München, Neuherberg, Germany;2. Clinical Research Unit, Centre of Internal Medicine, Justus Liebig University, Giessen, Germany;3. Clinical Research Unit, Centre of Internal Medicine, Justus Liebig University, Giessen, Germany Cell and Developmental Biology, Weill Cornell Medicine Qatar, Doha, Qatar;4. Institute of Experimental Biomedicine – Chair I, University Hospital and Rudolf Virchow Center, Würzburg, Germany;5. Department of Biochemistry, Medical Faculty, Justus-Liebig-University, Giessen, Germany |
Abstract: | Platelet activation and thrombus formation have been implicated to be detrimental for intraportal pancreatic islet transplants. The platelet-specific collagen receptor glycoprotein VI (GPVI) plays a key role in thrombosis through cellular activation and the subsequent release of secondary mediators. In aggregometry and in a microfluidic dynamic assay system modeling flow in the portal vein, pancreatic islets promoted platelet aggregation and triggered thrombus formation, respectively. While platelet GPVI deficiency did not affect the initiation of these events, it was found to destabilize platelet aggregates and thrombi in this process. Interestingly, while no major difference was detected in early thrombus formation after intraportal islet transplantation, genetic GPVI deficiency or acute anti-GPVI treatment led to an inferior graft survival and function in both syngeneic mouse islet transplantation and xenogeneic human islet transplantation models. These results demonstrate that platelet GPVI signaling is indispensable in stable thrombus formation induced by pancreatic islets. GPVI deficiency resulted in thrombus destabilization and inferior islet engraftment indicating that thrombus formation is necessary for a successful intraportal islet transplantation in which platelets are active modulators. |